BACKGROUND: While clinical outcomes following induction chemotherapy and stereotactic body radiation therapy (SBRT) have been reported for borderline resectable pancreatic cancer (BRPC) patients, pathologic response has not previously been described. METHODS: This single-institution retrospective review evaluated BRPC patients who completed induction gemcitabine-based chemotherapy followed by SBRT and surgical resection. Each surgical specimen was assigned two tumor regression grades (TRG), one using the College of American Pathologists (CAP) criteria and one using the MD Anderson Cancer Center (MDACC) criteria. Overall survival (OS) and progression free survival (PFS) were correlated to TRG score. RESULTS: We evaluated 36 patients with a median follow-up of 13.8 months (range, 6.1-24.8 months). The most common induction chemotherapy regimen (82%) was GTX (gemcitabine, docetaxel, capecitabine). A median SBRT dose of 35 Gy (range, 30-40 Gy) in 5 fractions was delivered to the region of vascular involvement. The margin-negative resection rate was 97.2%. Improved response according to MDACC grade trended towards superior PFS (P=061), but not OS. Any neoadjuvant treatment effect according to MDACC scoring (IIa-IV vs. I) was associated with improved OS and PFS (both P=0.019). We found no relationship between CAP score and OS or PFS. CONCLUSIONS: These data suggest that the increased pathologic response after induction chemotherapy and SBRT is correlated with improved survival for BRPC patients.
BACKGROUND: While clinical outcomes following induction chemotherapy and stereotactic body radiation therapy (SBRT) have been reported for borderline resectable pancreatic cancer (BRPC) patients, pathologic response has not previously been described. METHODS: This single-institution retrospective review evaluated BRPC patients who completed induction gemcitabine-based chemotherapy followed by SBRT and surgical resection. Each surgical specimen was assigned two tumor regression grades (TRG), one using the College of American Pathologists (CAP) criteria and one using the MD Anderson Cancer Center (MDACC) criteria. Overall survival (OS) and progression free survival (PFS) were correlated to TRG score. RESULTS: We evaluated 36 patients with a median follow-up of 13.8 months (range, 6.1-24.8 months). The most common induction chemotherapy regimen (82%) was GTX (gemcitabine, docetaxel, capecitabine). A median SBRT dose of 35 Gy (range, 30-40 Gy) in 5 fractions was delivered to the region of vascular involvement. The margin-negative resection rate was 97.2%. Improved response according to MDACC grade trended towards superior PFS (P=061), but not OS. Any neoadjuvant treatment effect according to MDACC scoring (IIa-IV vs. I) was associated with improved OS and PFS (both P=0.019). We found no relationship between CAP score and OS or PFS. CONCLUSIONS: These data suggest that the increased pathologic response after induction chemotherapy and SBRT is correlated with improved survival for BRPC patients.
Entities:
Keywords:
Radiation therapy (RT); chemotherapy; pancreatic cancer
Authors: Jeannelyn S Estrella; Asif Rashid; Jason B Fleming; Matthew H Katz; Jeffrey E Lee; Robert A Wolf; Gauri R Varadhachary; Peter W T Pisters; Eddie K Abdalla; Jean-Nicolas Vauthey; Hua Wang; Henry F Gomez; Douglas B Evans; James L Abbruzzese; Huamin Wang Journal: Cancer Date: 2011-07-06 Impact factor: 6.860
Authors: T M Breslin; K R Hess; D B Harbison; M E Jean; K R Cleary; A P Dackiw; R A Wolff; J L Abbruzzese; N A Janjan; C H Crane; J N Vauthey; J E Lee; P W Pisters; D B Evans Journal: Ann Surg Oncol Date: 2001-03 Impact factor: 5.344
Authors: Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher Journal: Ann Surg Date: 2005-11 Impact factor: 12.969
Authors: Jordan Kharofa; Susan Tsai; Tracy Kelly; Clint Wood; Ben George; Paul Ritch; Lauren Wiebe; Kathleen Christians; Douglas B Evans; Beth Erickson Journal: Radiother Oncol Date: 2014-10-15 Impact factor: 6.280
Authors: Rebekah R White; H Bill Xie; Marcia R Gottfried; Brian G Czito; Herbert I Hurwitz; Michael A Morse; Gerald C Blobe; Erik K Paulson; John Baillie; M Stanley Branch; Paul S Jowell; Bryan M Clary; Theodore N Pappas; Douglas S Tyler Journal: Ann Surg Oncol Date: 2005-03-03 Impact factor: 5.344
Authors: Timothy J Kinsella; Yuji Seo; Joseph Willis; Thomas A Stellato; Christopher T Siegel; Deborah Harpp; James K Willson; Joseph Gibbons; Juan R Sanabria; Jeffrey M Hardacre; James P Schulak Journal: Am J Clin Oncol Date: 2008-10 Impact factor: 2.339
Authors: Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar Journal: Int J Radiat Oncol Biol Phys Date: 2013-04-05 Impact factor: 7.038
Authors: Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: Malolan S Rajagopalan; Dwight E Heron; Rodney E Wegner; Herbert J Zeh; Nathan Bahary; Alyssa M Krasinskas; Barry Lembersky; Randall Brand; A James Moser; Annette E Quinn; Steven A Burton Journal: Radiat Oncol Date: 2013-10-31 Impact factor: 3.481
Authors: Jordan M Cloyd; Huamin Wang; Michael E Egger; Ching-Wei D Tzeng; Laura R Prakash; Anirban Maitra; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Michael J Overman; Eugene J Koay; Prajnan Das; Joseph M Herman; Michael P Kim; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz Journal: JAMA Surg Date: 2017-11-01 Impact factor: 14.766
Authors: William H Jin; Eric A Mellon; Jessica M Frakes; Gilbert Z Murimwa; Pamela J Hodul; Jose M Pimiento; Mokenge P Malafa; Sarah E Hoffe Journal: J Gastrointest Oncol Date: 2018-02
Authors: Giampaolo Perri; Laura Prakash; Huamin Wang; Priya Bhosale; Gauri R Varadhachary; Robert Wolff; David Fogelman; Michael Overman; Shubham Pant; Milind Javle; Eugene Koay; Joseph Herman; Michael Kim; Naruhiko Ikoma; Ching-Wei Tzeng; Jeffrey E Lee; Matthew H G Katz Journal: Ann Surg Date: 2021-04-01 Impact factor: 13.787
Authors: Brandon C Chapman; Ana Gleisner; Devin Rigg; Wells Messersmith; Alessandro Paniccia; Cheryl Meguid; Csaba Gajdos; Martin D McCarter; Richard D Schulick; Barish H Edil Journal: JOP Date: 2018-03-30
Authors: Jin He; Alex B Blair; Vincent P Groot; Ammar A Javed; Richard A Burkhart; Georgios Gemenetzis; Ralph H Hruban; Kevin M Waters; Justin Poling; Lei Zheng; Daniel Laheru; Joseph M Herman; Martin A Makary; Matthew J Weiss; John L Cameron; Christopher L Wolfgang Journal: Ann Surg Date: 2018-07 Impact factor: 13.787
Authors: Roberto Alva-Ruiz; Lavanya Yohanathan; Jennifer A Yonkus; Amro M Abdelrahman; Lindsey A Gregory; Thorvadur R Halfdanarson; Amit Mahipal; Robert R McWilliams; Wen Wee Ma; Christopher L Hallemeier; Rondell P Graham; Travis E Grotz; Rory L Smoot; Sean P Cleary; David M Nagorney; Michael L Kendrick; Mark J Truty Journal: Ann Surg Oncol Date: 2021-11-01 Impact factor: 5.344